BioCentury
ARTICLE | Company News

Astellas cans MAA plans for tivozanib

May 25, 2013 12:53 AM UTC

Aveo Pharmaceuticals Inc. (NASDAQ:AVEO) disclosed in an SEC filing late Thursday that partner Astellas Pharma Inc. (Tokyo:4503) said it no longer plans to submit an MAA to EMA for tivozanib ( AV-951, ASP4130) to treat advanced renal cell carcinoma (RCC). According to Aveo, Astellas does not intend to fund future trials in RCC. Aveo said it is also evaluating the path forward for the indication. Tivozanib is in Phase II testing for breast and colorectal cancer. Astellas could not be reached for comment. Aveo was up $0.01 to $2.71 on Friday. ...